Prospective randomised trial of stented versus stentless bioprosthesis for aortic valve replacement (AVR)
| ISRCTN | ISRCTN56511757 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN56511757 |
| Protocol serial number | P00715 |
| Sponsor | Papworth Hospital NHS Trust (UK) |
| Funder | Edwards LifeSciences Ltd (UK) - Industrial grant |
- Submission date
- 16/05/2005
- Registration date
- 08/07/2005
- Last edited
- 04/10/2007
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Mr Steven Tsui
Scientific
Scientific
Surgical Unit
Papworth Hospital NHS Trust
Papworth Everard
CB3 8RE
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | To find out which prosthetic valves represent the better option for patients requiring AVR. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Aortic valve replacement |
| Intervention | Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards Lifesciences). |
| Intervention type | Other |
| Primary outcome measure(s) |
Post-operative pressure gradient across the prosthetic valve and effective valve orifice area. |
| Key secondary outcome measure(s) |
No secondary outcome measures |
| Completion date | 05/07/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Senior |
| Sex | All |
| Target sample size at registration | 240 |
| Key inclusion criteria | Inclusion criteria: 1. Patients who require elective AVR with a tissue valve for symptomatic aortic valve stenosis (peak valve gradient equal to or greater than 50 mmHg as measured by echocardiography), with or without concomitant artery bypass grafting 2. Patients = 65 years of age at the time of surgery |
| Key exclusion criteria | 1. Patients who are already enrolled in another major cardiovascular trial 2. AVR performed primarily for aortic valve regurgitation 3. Active aortic valve infection 4. Active malignant disease 5. Renal failure requiring dialysis 6. Any previous cardiac surgery 7. The need for additional cardiac procedures other than coronary artery bypass grafting 8. Emergency operations 9. Patients unable to give informed consent |
| Date of first enrolment | 01/03/2001 |
| Date of final enrolment | 05/07/2005 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Surgical Unit
Papworth Everard
CB3 8RE
United Kingdom
CB3 8RE
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Results | 01/06/2007 | Yes | No |